knowledge -WSS

knowledge

author：Wikipedia 2025-09-29 19:58:12 - browse：385

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： As AI in medicine takes off, can 'human in the loop' prevent harm?

hotspot

WSS

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Venture capitalist Bob Kocher on the state of digital health

Medicare coverage of Wegovy, once blocked, now looks possible

Helping hospitals and community health centers plan for resilience

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

entertainment

knowledge

knowledge

Supreme Court strikes down use of affirmative action

Addiction experts warn against a second 'war on drugs'

Guidelines to prevent youth baseball injuries need more muscle

Helping hospitals and community health centers plan for resilience

FDA approval of Sarepta Duchenne genetic therapy gives me hope

As AI in medicine takes off, can 'human in the loop' prevent harm?

Cancer drug shortages should be causing more outrage

How many hemophilia patients actually want gene therapy?

At least 13 dead in Texas as scorching temps continue

Solving academic medical centers' existential crisis

hotspot

FDA advisers back CAR

Amid AI frenzy, a top HHS official's quest to create safeguards

Boston's new lab space is opening empty

Second House panel advances two

John Green on his newest strategy for fighting tuberculosis

EPA limits use of carcinogenic gas for sterilizing medical devices

explore

knowledge

hotspot

hotspot